Last reviewed · How we verify
Inoculation in upper arm deltoid
An inoculation administered intramuscularly in the deltoid muscle that delivers a vaccine antigen to stimulate immune response against a specific pathogen.
An inoculation administered intramuscularly in the deltoid muscle that delivers a vaccine antigen to stimulate immune response against a specific pathogen. Used for Disease prevention (specific indication unknown without vaccine type specification).
At a glance
| Generic name | Inoculation in upper arm deltoid |
|---|---|
| Sponsor | Beijing Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine is injected into the deltoid muscle of the upper arm, where it triggers both humoral (antibody) and cellular immune responses. The specific mechanism depends on the vaccine type (inactivated, live attenuated, mRNA, protein subunit, etc.), but generally involves presentation of antigens to immune cells to generate protective immunity against the target disease.
Approved indications
- Disease prevention (specific indication unknown without vaccine type specification)
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue
- Myalgia
- Headache
Key clinical trials
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) (PHASE1)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa (PHASE2)
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: